Our Paradigm for the Treatment of Knee Osteoarthritis
At Kolon TissueGene, we are developing advanced cell therapies to target various degenerative musculoskeletal diseases.
explore our platform technology
An Allogeneic Cell-Based Gene Therapy for Knee Osteoarthritis
TG-C is an investigational drug, currently completing Phase III clinical trials as a potential treatment for knee osteoarthritis (KOA). It has been designed to treat KOA by reducing pain, increasing function, and slowing the progression of the disease.
learn more about TG-C
Developing Advanced Cell Therapies for the Treatment of Orthopedic Disorders and Unmet Medical Needs
Kolon TissueGene is a US-based clinical-stage biopharmaceutical company developing advanced cell therapies.
TG-C